KALA BIO (KALA) Competitors $5.73 -0.32 (-5.29%) Closing price 03/31/2025 04:00 PM EasternExtended Trading$5.80 +0.07 (+1.22%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALA vs. LRMR, HURA, NLTX, CYBN, ADCT, SCPH, ACTU, NKTX, CGEN, and OGIShould you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include Larimar Therapeutics (LRMR), TuHURA Biosciences (HURA), Neoleukin Therapeutics (NLTX), Cybin (CYBN), ADC Therapeutics (ADCT), scPharmaceuticals (SCPH), Actuate Therapeutics (ACTU), Nkarta (NKTX), Compugen (CGEN), and Organigram (OGI). These companies are all part of the "pharmaceutical products" industry. KALA BIO vs. Larimar Therapeutics TuHURA Biosciences Neoleukin Therapeutics Cybin ADC Therapeutics scPharmaceuticals Actuate Therapeutics Nkarta Compugen Organigram Larimar Therapeutics (NASDAQ:LRMR) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking. Is LRMR or KALA more profitable? Larimar Therapeutics' return on equity of -35.87% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets Larimar TherapeuticsN/A -35.87% -32.37% KALA BIO N/A -448.61%-69.37% Which has better earnings and valuation, LRMR or KALA? Larimar Therapeutics has higher earnings, but lower revenue than KALA BIO. Larimar Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLarimar TherapeuticsN/AN/A-$36.95M-$1.30-1.65KALA BIO$3.89M8.97-$42.20M-$12.47-0.46 Does the MarketBeat Community prefer LRMR or KALA? KALA BIO received 256 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. However, 71.43% of users gave Larimar Therapeutics an outperform vote while only 66.89% of users gave KALA BIO an outperform vote. CompanyUnderperformOutperformLarimar TherapeuticsOutperform Votes4571.43% Underperform Votes1828.57% KALA BIOOutperform Votes30166.89% Underperform Votes14933.11% Which has more risk & volatility, LRMR or KALA? Larimar Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, KALA BIO has a beta of -2.19, suggesting that its share price is 319% less volatile than the S&P 500. Does the media favor LRMR or KALA? In the previous week, Larimar Therapeutics had 37 more articles in the media than KALA BIO. MarketBeat recorded 41 mentions for Larimar Therapeutics and 4 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.97 beat Larimar Therapeutics' score of 0.04 indicating that KALA BIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral KALA BIO 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in LRMR or KALA? 91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 3.5% of Larimar Therapeutics shares are owned by insiders. Comparatively, 8.3% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend LRMR or KALA? Larimar Therapeutics presently has a consensus target price of $20.22, indicating a potential upside of 840.57%. KALA BIO has a consensus target price of $15.00, indicating a potential upside of 161.78%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Larimar Therapeutics is more favorable than KALA BIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08KALA BIO 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryLarimar Therapeutics beats KALA BIO on 12 of the 17 factors compared between the two stocks. Remove Ads Get KALA BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALA vs. The Competition Export to ExcelMetricKALA BIOPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.90M$6.89B$5.63B$7.79BDividend YieldN/A2.81%5.37%4.04%P/E Ratio-0.467.4223.6118.68Price / Sales8.97207.04373.3989.80Price / CashN/A65.6738.1734.64Price / Book2.056.206.734.12Net Income-$42.20M$142.11M$3.20B$247.10M7 Day Performance-14.48%-7.28%-5.33%-3.82%1 Month Performance-17.32%-10.45%-0.40%-6.61%1 Year Performance-27.65%-12.86%7.89%-1.67% KALA BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALAKALA BIO3.9127 of 5 stars$5.73-5.3%$15.00+161.8%-28.1%$34.90M$3.89M-0.4630Earnings ReportUpcoming EarningsNews CoverageGap DownLRMRLarimar Therapeutics1.9133 of 5 stars$2.15-8.5%$20.22+840.6%-71.7%$137.66MN/A-1.8730Gap DownHURATuHURA BiosciencesN/A$3.23-8.5%$13.00+302.5%N/A$136.58MN/A0.00N/ANLTXNeoleukin TherapeuticsN/A$14.52-5.3%N/A-71.5%$136.46MN/A-4.6790CYBNCybin1.7637 of 5 stars$6.34-5.7%$86.00+1,256.5%N/A$136.16MN/A-1.4550Gap DownADCTADC Therapeutics2.2885 of 5 stars$1.41-5.7%$7.75+451.6%-68.7%$135.85M$70.72M-0.59310Earnings ReportAnalyst ForecastShort Interest ↓News CoverageGap DownSCPHscPharmaceuticals4.0201 of 5 stars$2.63-5.4%$14.00+432.3%-47.6%$132.25M$36.33M-1.3830Positive NewsHigh Trading VolumeACTUActuate TherapeuticsN/A$6.77-14.3%$20.00+195.4%N/A$132.23MN/A0.0010NKTXNkarta2.637 of 5 stars$1.84-8.0%$14.86+707.5%-83.0%$130.56MN/A-0.98140Earnings ReportAnalyst RevisionNews CoverageGap DownCGENCompugen1.9729 of 5 stars$1.46-4.6%$4.00+174.0%-43.4%$130.29M$27.86M73.0070OGIOrganigram0.7088 of 5 stars$1.01-1.9%N/A-53.0%$127.52M$166.12M-2.66860Gap Down Remove Ads Related Companies and Tools Related Companies Larimar Therapeutics Competitors TuHURA Biosciences Competitors Neoleukin Therapeutics Competitors Cybin Competitors ADC Therapeutics Competitors scPharmaceuticals Competitors Actuate Therapeutics Competitors Nkarta Competitors Compugen Competitors Organigram Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALA) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
